Julie Gerberding and CDC Revolving Door

8/2/2019 Julie Gerberding and CDC Revolving Door

1/3

Dr. Julie Gerberding Named President of Merck Vaccines

WHITEHOUSE STATION, N.J. Dec. 21, 2009 Merck & Co., Inc. (NYSE:

MRK) today announced that Dr. Julie Gerberding has been named

president of Merck Vaccines, effective January 25, 2010.

Dr. Gerberding led the Centers for Disease Control and Prevention (CDC)

as director from 2002 to 2009. During her tenure at CDC, Dr. Gerberding

led the agency during more than 40 emergency response initiatives for

health crises including anthrax bioterrorism, food-borne disease outbreaks,

and natural disasters, and advised governments around the world on

urgent public health issues such as SARS, AIDS, and obesity.

Vaccines are a cornerstone of Merck's commitment to health and wellness," said Richard T.

Clark, chairman and chief executive officer, Merck & Co., Inc. "We are del ighted to welcome an

expert of Dr. Gerberding's caliber to Merck. As a preeminent authority in public health, infectious

diseases and vaccines, Dr. Gerberding is the ideal choice to lead Merck's engagement with

organizations around the world that share our commitment to the use of vaccines to prevent

disease and save lives."

"Ive had the privilege in my previous work in academia and in the federal government to be a

passionate advocate for public health priorities such as vaccines, which are an imperative

component of global health development," said Dr. Gerberding. "I am very excited to be joining

Merck where I can help to expand access to vaccines around the world."

Dr. Gerberding will lead the company's $5 billion global vaccine business. Merck currently

markets a broad range of pediatric, adolescent and adult vaccines and is a leading provider of

vaccines in countries around the world; in the U.S., Merck markets vaccines for 12 of the 17

diseases for which the U.S. Advisory Committee for Immunization Practices currently

recommends vaccines. She will be responsible for the commercialization of the current portfolio

of vaccines, planning for the introduction of vaccines from the company's robust vaccine

pipeline, and accelerating Merck's on-going efforts to broaden access to its vaccines in the

developing world. Dr. Gerberding wil l also collaborate with leaders of Merck Manufacturing

Division and Merck Research Laboratories to manage the critical linkages between basic

research, late-stage development and manufacturing to expand Merck's vaccine offerings

throughout the world.

She received her undergraduate degree and her M.D. from Case Western Reserve University.

Her internship, residency, and clinical pharmacology training were all at the University of

California, San Francisco (UCSF), where she worked in a range of clinical, research and

teaching roles prior to joining the CDC in 1998. Dr. Gerberding received her Masters of Public

Health at the University of California, Berkeley.

She is a member of the Institute of Medicine and a fellow of the Infectious Diseases Society of

America and the American College of Physicians, and is board certified in Internal Medicine and


2/3

Infectious Diseases. She is also a Clinical Professor of Infectious Diseases at Emory University

and an Adjunct Associate Professor of Medicine in Infectious Diseases at UCSF.

Dr. Gerberding has received more than 50 awards and honors, including the United States

Department of Health and Human Services (DHHS) Distinguished Service Award for her

leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks. She was

named to Forbes Magazine's 100 Most Powerful Women in the world in 2005, 2006, 2007, and

2008 and was named to TIME Magazine's 100 Most Influential People in the World in 2004.

About Merck

Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic

therapies, and consumer and animal products, we work with customers and operate in more

than 140 countries to deliver innovative health solutions. We also demonstrate our commitment

to increasing access to healthcare through far-reaching programs that donate and deliver our

products to the people who need them. Merck. Be Well. For more information, visit

www.merck.com.

Forward Looking Statement

This news release includes forward-looking statements within the meaning of the safe harbor

provisions of the United States Private Securities Litigation Reform Act of 1995. Such statementsmay include, but are not limited to, statements about the benefits of the merger between Merck

and Schering-Plough, including future financial and operating results, the combined companys

plans, objectives, expectations and intentions and other statements that are not historical facts.

Such statements are based upon the current beliefs and expectations of Mercks management

and are subject to significant risks and uncertainties. Actual results may differ from those set

forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in

the forward-looking statements: the possibility that the expected synergies from the merger of

Merck and Schering-Plough will not be realized, or will not be realized within the expected time

period, due to, among other things, the impact of pharmaceutical industry regulation and

pending legislation that could affect the pharmaceutical industry; the risk that the businesses will

not be integrated successfully; disruption from the merger making it more difficult to maintain

business and operational relationships; Mercks ability to accurately predict future market

conditions; dependence on the effectiveness of Mercks patents and other protections for

innovative products; the risk of new and changing regulation and health policies in the U.S. and

internationally and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a

result of new information, future events or otherwise. Additional factors that could cause results

to differ materially from those described in the forward-looking statements can be found inMercks 2008 Annual Report on Form 10-K, Schering-Ploughs Quarterly Report on Form 10-Q

for the quarterly period ended September 30, 2009, the proxy statement filed by Merck on June

25, 2009 and each companys other filings with the Securities and Exchange Commission

(SEC) available at the SECs Internet site: www.sec.gov.

# # #


3/3

top

Copyright 2009 Merck Sharp & Dohme Corp., a subsidiary ofMerck & Co., Inc., Whitehouse Station, N.J., U.S.A. Privacy Terms of Use

Site Map

Documents

Julie Gerberding and CDC Revolving Door